Citius Oncology, Inc.
CTOR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001851484
No open-market purchases or sales by Citius Oncology, Inc. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $9.20M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Citius Oncology, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 14 | 19 | +5 |
| Shares | 14.2M | 14.1M | −102.5K (−0.7%) |
| Value | $8.83M | $9.20M | +$366.4K (+4.2%) |
New holders (7)
Institutions that held Citius Oncology, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 90,586 | $58.9K | 0.00% |
| Virtu Financial LLC | 21,877 | $14.0K | 0.00% |
| XTX Topco Ltd | 20,638 | $13.4K | 0.00% |
| Tower Research Capital LLC (TRC) | 13,816 | $8.98K | 0.00% |
| Wells Fargo & Company | 500 | $325 | 0.00% |
| Barclays PLC | 90 | $59 | 0.00% |
| Morgan Stanley | 23 | $15 | 0.00% |
Sold out (2)
Institutions that held Citius Oncology, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| BlackRock, Inc. | 47,454 | $29.4K |
| Royal Bank of Canada | 186 | $0 |